Evidence map›Paper›PMID 36833366›Full record

ArticleGenes2023

Spotlight on

Joana Ropio, Martina Prochazkova-Carlotti, Rui Batista, Ana Pestana, Alain Chebly, Jacky Ferrer, Yamina Idrissi, David Cappellen, Cecília Durães, Paula Boaventura and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. The C250T Mutation ofCancers · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 3 countries.

Joana RopioBRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France.
Martina Prochazkova-CarlottiBRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France.
Rui BatistaInstitute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal.
Ana PestanaInstitute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal.
Alain CheblyBRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France.ORCID 0000-0001-5582-2923
Jacky FerrerBRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France.
Yamina IdrissiBRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France.
David CappellenBRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France.
Cecília DurãesInstitute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal.ORCID 0000-0001-9282-0708
Paula BoaventuraInstitute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Cancer Biology Group, Porto University, 4200-465 Porto, Portugal.ORCID 0000-0003-4869-8148
João VinagreInstitute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal.ORCID 0000-0002-0871-1427
Lamia Azzi-MartinBRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France.
Sandrine PoglioBRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France.
José CabeçadasDermatology Departement, Instituto Português de Oncologia de Lisboa (IPO-L), 1099-023 Lisbon, Portugal.ORCID 0000-0001-6232-1596
Manuel António CamposInstitute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal.ORCID 0000-0002-6810-790X
Marie Beylot-BarryBRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France.
Manuel Sobrinho-SimõesInstitute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal.
Jean-Philippe MerlioBRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France.ORCID 0000-0002-0305-0850
Paula SoaresInstitute for Research and Innovation in Health (I3S), Porto University, 4200-135 Porto, Portugal.ORCID 0000-0001-9607-6998
Edith ChevretBRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France.
Université de Bordeaux · FRUniversidade do Porto · PTIPO Porto · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a major cancer hallmark, there is a sustained interest in understanding the telomerase contribution to carcinogenesis in order to therapeutically target this enzyme. This is particularly relevant in primary cutaneous T-cell lymphomas (CTCL), a malignancy showing telomerase dysregulation with few investigative data available. In CTCL, we examined the mechanisms involved in telomerase transcriptional activation and activity regulation. We analyzed 94 CTCL patients from a Franco-Portuguese cohort, as well as 8 cell lines, in comparison to 101 healthy controls. Our results showed that not only polymorphisms (SNPs) located at the promoter of human telomerase reverse transcriptase (

Indexed as

Lymphoma, T-Cell, CutaneousTelomeraseCell LineGene Expression RegulationHumansPromoter Regions, GeneticTelomeraseTERT protein, humanCTCLhTERTpromoter mutationsSNPsplicing variantstelomerase

Identifiers

PMID36833366
PMCPMC9956048
OpenAlexW4319786662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.